TMCnet News
Transparency notificationMechelen, Belgium; 18 December 2017; 7.30 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Gilead Sciences, Inc. Pursuant to Belgian transparency legislation[1], Galapagos received a transparency notification on 13 December 2017 from Gilead Sciences, Inc., who notified that its subsidiary Gilead Biopharmaceutics Ireland UC transferred its holding of 6,760,701 Galapagos shares on 7 December 2017 to its subsidiary Gilead Therapeutics A1 Unlimited Company. This shareholding represents 13.27% of Galapagos' currently outstanding 50,936,778 shares, and represents no change in the number of shares compared to the previous transparency notification from Gilead Sciences Inc. on 20 January 2016. The full transparency notice is available on the Galapagos website. About Galapagos Contact Investors: Elizabeth Goodwin VP IR & Corporate Communications +1 781 460 1784 Paul van der Horst Media: [1] Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market. Attachments: //www.globenewswire.com/NewsRoom/AttachmentNg/189f528e-73b2-48e6-bb32-915ac16ee355 |